SEARCH

SEARCH BY CITATION

References

  • Aapro MS, Kirchner V, Terrey JP (1994). The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer 69: 957960.
  • Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research (2003). A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 14: 291297.
  • Abrahamov A, Abrahamov A, Mechoulam R (1995). An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56: 20972102.
  • Andrews PL, Bhandari P (1993). Resiniferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 32: 799806.
  • Andrews PL, Horn CC (2006). Signals for nausea and emesis: implications for models diseases. Auton Neurosci 125: 100115.
  • Andrews PL, Torii Y, Saito H, Matsuki N (1996). The pharmacology of the emetic response to upper gastrointestinal tract stimulation in Suncus murinus. Eur J Pharmacol 307: 305313.
  • Andrews PL, Okada F, Woods AJ, Hagiwara H, Kakaimoto S, Toyoda M et al. (2000). The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew. Br J Pharmacol 130: 12471254.
  • Ballatori E, Roila F (2003). Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1: 46.
  • Barann M, Molderings G, Bruss M, Bonisch H, Urban BW, Gothert M (2002). Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137: 589596.
  • Bartlett N, Koczwara B (2002). Control of nausea and vomiting after chemotherapy: what is the evidence? Int Med J 32: 401407.
  • Berger B (1972). Conditioning of food aversions by injections of psychoactive drugs. J Comp Phys Psychol 81: 2126.
  • Billig I, Yates BJ, Rinaman L (2001). Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cholecystokinin. Am J Physiol Regul Integr Comp Physiol 281: R1243R1255.
  • Blier P, de Montigny C (1987). Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1: 470480.
  • Borrison HL, Wang SC (1953). Physiology and pharmacology of vomiting. Pharmacol Rev 5: 193230.
  • Breslin PA, Spector AC, Grill HJ (1992). A quantitative comparison of taste reactivity behaviors to sucrose before and after lithium chloride pairings: a unidimensional account of palatability. Behav Neurosci 106: 820836.
  • Carey MP, Burish TG, Brenner DE (1983). Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med 99: 106114.
  • Chambers AP, Vemuri VK, Peng Y, Wood JT, Olszewska T, Pittman QJ et al. (2007). A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physciol Regul Integr Comp Physiol 293: R2185R2193.
  • Cluny NL, Naylor RJ, Whittle BA, Javid FA (2008). The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. Basic Clin Pharmacol Toxicol 103: 150156.
  • Cluny NL, Chambers AP, Limebeer CL, Keenan CM, Bedard H, Vemuri VK et al. (2010). A novel, peripherally resitricted cannabinoid 1 (CB1) receptor antagonist AM6545 recuces food intake and body weight, but does not cause malaise in rodents. Br J Pharmacol 161: 629642.
  • Coil JD, Hankins WG, Jenden DJ, Garcia J (1978). The attenuation of a specific cue-to-consequence association by antiemetic agents. Psychopharmacology 56: 2125.
  • Costall B, Domeney AM, Naylor RJ, Tattersall FD (1986). 5-Hydroxytryptamine receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25: 959961.
  • Crawford SM, Buckman R (1986). Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatin: a double blind study. Med Oncol Tumor Pharmacother 3: 3942.
  • Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, DiMarzo V (2006). immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139: 14051415.
  • Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA (2007). Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology 190: 135143.
  • Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M et al. (1988). A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24: 685689.
  • Darmani NA (2001a). Delta-9-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24: 198203.
  • Darmani NA (2001b). Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptor in the least shrew. Pharmacol Biochem Behav 69: 239249.
  • Darmani NA (2001c). The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol 430: 4958.
  • Darmani NA (2002). The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by Delta (9)-tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther 300: 3442.
  • Darmani NA, Johnson CJ (2004). Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488: 201212.
  • Darmani NA, Janoyan JJ, Kumar N, Crim JL (2003). Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 75: 777787.
  • Darmani NA, McClanahan BA, Trinh C, Petrosino S, Valenti M, DiMarzo V (2005). Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 49: 502513.
  • Davey VA, Biederman GB (1998). Conditioned antisickness: indirect evidence from rats and direct evidence from ferrets that conditioning alleviates drug-induced nausea and emesis. J Exp Psychol Anim Behav Process 24: 483491.
  • deBoer-Dennert M, deWit R, Schmitz I, Djontono J, Beurden V, Stoter G et al. (1997). Patient perceptions of the side-effects of chemothareapy: the influence of 5HT3 antagonists. Br J Cancer 76: 10551061.
  • Di Marzo V, Fontana A (1995). Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’. Prostaglandins Leukot Essent Fatty Acids 53: 111.
  • Di Marzo V, Lastres-Becker I, Bisogno T, DePetrocellis L, Milone A, Davis JB et al. (2001). Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262: 275284.
  • Fan P (1995). Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73: 907910.
  • Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G et al. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl ceramic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352358.
  • Feigenbaum JJ, Richmond SA, Weissman Y, Mechoulam R (1989). Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol 4: 159165.
  • Ferrari F, Ottanik A, Giuliani D (1999). Cannabimimetic activity in rats and pigeons of HU-210, a potent antiemetic drug. Pharmacol Biochem Behav 62: 7580.
  • Gadusek FJ, Kalat JW (1975). Effects of scopolamine on retention of taste-aversion learning in rats. Physiol Psychol 3: 130132.
  • Gamzu E (1977). The multifaceted nature of taste aversion inducing agents: is there a single common factor? In: Barker L, Domjan M, Best M (eds). Learning Mechanisms of Food Selection. Baylor Univ. Press: Waco, TX, pp. 447511.
  • Garcia J, Hankins WG, Rusiniak KW (1974). Behavioral regulation of the milieu interne in man and rat. Science 185: 824831.
  • Garcia J, Rusiniak KW, Brett LP (1977). Conditioning food-illness aversions in wild animals: caveant canonici. In: Davis H, Hurowitz HMB (eds). Operant Pavlovian Interactions. Lawrence Erlbaum: Hillsdale: NJ, pp. 273316.
  • Gorzalka B, Hanson L, Harrington J, Killam S, Campbell-Meiklejohn D (2003). Conditioned taste aversion: modulation by 5-HT receptor activity and corticosterone. Eur J Pharamcol 47: 129134.
  • Goudie AJ, Stolerman IP, Demellweek C, D'Mello GD (1982). Does conditioned nausea mediate drug-induced conditioned taste aversion? Psychopharmacology 78: 277282.
  • Grelot L, Milano S, LeStunff H (1995). Does 5-HT play a role in the delayed phase of cisplatin-induced emesis? In: Reynolds J, Andrews PLR, Davis CJ (eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford Clinical Communications: Oxford, pp. 181191.
  • Grigson PS, Twining R (2002). Cocaine-induced suppression of saccharin intake: a model of drug-induced devaluation of natural rewards. Behav Neurosci 116: 321333.
  • Grill HC, Norgren R (1978). The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 143: 263279.
  • Grinspoon L, Bakalar JB (1993). Marijuana: The Forbidden Medicine. Yale University Press: New Haven.
  • Gupta YK, Sharma SS (2002). Involvement of 5-HT1A and 5-HT2 receptor in cisplatin induced emesis in dogs. Indian J Physiol Pharmacol 46: 463467.
  • Hall W, Christie M, Currow D (2005). Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6: 3542.
  • Hermann H, Marsicano G, Lutz B (2002). Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109: 541460.
  • Hermann H, DePetrocellis L, Bisogno T, Schiano-Morello A, Lutz B, DiMarzo V (2003). Dual effect of cannabinoid CB1 recptor stimulation on a vanniloid VR receptor-mediated response. Cell Mol Life Sci 60: 607616.
  • Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R et al. (2003). Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39: 10741080.
  • Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003). Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 97: 28802886.
  • Hillsley K, Grundy D (1998). Serotonin and cholecystokinin activate different populations of rat mesenteric vagal afferents. Neurosci Lett 255: 6366.
  • Himmi T, Dallaporta M, Perrin J, Orsini JC (1996). Neuronal responses to delta9-tetrahyrocannabinol in the solitary tract nucleus. Eur J Pharmacol 312: 273279.
  • Himmi T, Perrin J, El Ouazzani T, Orsini JC (1998). Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur J Pharmacol 359: 4954.
  • Hornby PJ (2001). Central neurocircuitry associated with emesis. Am J Med 1111: 106S1112.
  • Howlett AC, Barth F, Bonner TI, Cabral P, Casellaa G, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 54: 161202.
  • Iversen LL (2000). The Science of Marijuana. Oxford University Press: New York.
  • Javid FA, Naylor RJ (2006). The effect of the 5-HT1A receptor agonist, 8-OH-DPAT, on motion-induced emesis in Suncus murinus. Pharmacol Biochem Behav 5: 820826.
  • Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010). Multicenter, double-blind, randomized, placebo controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD Extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39: 167179.
  • Jordan K, Kasper C, Schmoll HJ (2005). Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 41: 199205.
  • Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I (1998). Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5HT) receptor. Biol Pharm Bull 21: 224226.
  • Kwiatkowska M, Parker LA, Burton P, Mechoulam R (2004). A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174: 254259.
  • Layeeque R, Siegel E, Kass R, Henry-Tillman RS, Colvert M, Mancino A et al. (2006). Prevention of nausea and vomiting following breast surgery. Am J Surg 191: 767772.
  • Limebeer CL, Parker LA (1999). Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned disgust reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport 26: 371384.
  • Limebeer CL, Parker LA (2000). Ondansetron interferes with the establishment and the expression of conditioned disgust reactions: a rat model of nausea. J Exp Psychol Anim Behav Process 26: 371384.
  • Limebeer CL, Parker LA (2003). The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacology 166: 120126.
  • Limebeer CL, Parker LA, Fletcher P (2004). 5,7-dihydroxytryptamine lesions of the dorsal and median raphe nuclei interfere with lithium-induced conditioned gaping, but not conditioned taste avoidance, in rats. Behav Neurosci 118: 13911399.
  • Limebeer CL, Hall G, Parker LA (2006). Exposure to a lithium-paired context elicits gaping in rats: a model of anticipatory nausea. Physiol Behav 88: 398403.
  • Limebeer CL, Krohn JP, Rock EM, Cross-Mellor SK, Parker LA, Ossenkopp KP (2008). Exposure to a context previously associated with toxin(LiCl)- or motion-induced sickness elicits conditioned gaping in rats: evidence in support of a model of anticipatory nausea. Behav Brain Res 187: 3340.
  • Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A et al. (2010). Inverse agonism of CB1 recpotrs potentiates LiCl-induced nausea: evidence from the conditioned gaping model in rats. Br J Pharmacol 161: 336349.
  • Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE et al. (2009a). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioural effects. Nat Chem Biol 5: 3744.
  • Long JZ, Nomura DK, Cravatt BF (2009b). Characterization of Monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16: 744753.
  • Lucot JB (1990). Effects of serotonin antagonists on motion sickness and its suppression by 8-OH-DPAT in cats. Pharmacol Biochem Behav 37: 283287.
  • Lucot JB, Crampton GH (1989). 8-OH DPAT suppresses vomiting in the cat elicited by motion, cisplatin, or xylazine. Pharmacol Biochem Behav 33: 627631.
  • McCarthy LE, Borison HL (1981). Anti-emetic activity of N-methyllevonantrobil and naboline in cisplatin treated cats. J Clin Pharmacol 21: 30S37S.
  • McLaughlin PJ, Winston KM, Limebeer CL, Parker LA, Makriyannis A, Salamone JD (2005). The cannabinoid antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology 180: 286293.
  • Matsuki N, Ueno S, Kaji T, Ishihara A, Wang CH, Saito H (1988). Emesis induced by cancer chemotherapeutic agents in the Suncus murinus: a new experimental model. Jpn J Pharmacol 48: 303306.
  • Meachum CL, Bernstein IL (1992). Behavioral conditioned responses to contextual and odor stimuli paired with LiCl administration. Physiol Behav 52: 895899.
  • Mechoulam R (2005). Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol 146: 913915.
  • Mechoulam R, Parker LA, Gallily R (2002). Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42: 11S19S.
  • Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM et al. (2007). Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23: 533543.
  • Miner WJ, Sanger GJ (1986). Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88: 497499.
  • Morrow GR, Dobkin PL (1988). Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: prevalence, etiology and behavioral interventions. Clin Psychol Rev 8: 517556.
  • Nesse RM, Carli T, Curtis GC, Kleinman PD (1980). Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 42: 3336.
  • Okada F, Torii Y, Saito H, Matsuki N (1994). Antiemetic effects of serotonergic 5-HT1A-receptor agonists in Suncus murinus. Jpn J Pharmacol 64: 109114.
  • Parker LA (1982). Nonconsummatory and consummatory behavioral CRs elicited by lithium-paired and amphetamine-paired flavors. Learn Motiv 13: 281303.
  • Parker LA (1995). Rewarding drugs produce taste avoidance, but not taste aversion. Neurosci Biobehav Rev 19: 143151.
  • Parker LA (1998). Emetic drugs produce conditioned rejection reactions in the taste reactivity test. J Psychophysiol 12: 313.
  • Parker LA (2003). Taste avoidance and taste aversion: evidence for two different processes. Learn Behav 31: 165172.
  • Parker LA, Kemp S (2001). Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV). Neuroreport 12: 749751.
  • Parker LA, Limebeer CL (2008). Cannabinoids in the management of nausea and vomiting. In: Kofalvi A (ed.). Cannabinoids and the Brain. Springer-Verlag Press: New York.
  • Parker LA, McLeod KB (1991). Chin rub CRs may reflect conditioned sickness elicited by a lithium-paired sucrose solution. Pharmacol Biochem Behav 40: 983986.
  • Parker LA, Mechoulam R (2003). Cannabinoid agonists and an antagonist modulate conditioned gaping in rats. Integr Physiol Behav Sci 38: 134146.
  • Parker LA, Corrick ML, Limebeer CL, Kwiatkowska M (2002a). Amphetamine and morphine produce a conditioned taste and place preference in the house musk shrew (Suncus murinus). J Exp Psychol Anim Behav Process 28: 7582.
  • Parker LA, Mechoulam R, Schlievert C (2002b). Cannabidiol, a non-psychoactive component of cannabis, and its dimethylheptyl homolg suppress nausea in an experimental model with rats. Neuroreport 13: 567570.
  • Parker LA, Mechoulam R, Shlievert C, Abbott L, Fudge ML, Burton P (2003). Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 166: 156162.
  • Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004). Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus. Psychopharmacology 171: 156161.
  • Parker LA, Limebeer CL, Kwiatkowska M (2005). Cannabinoids: effects on vomiting and nausea in animal model. In: Mechoulam R (ed.). Cannabinoids As Therapeutics. Birkhauser Verlag, Basel: Switzerland, pp. 183200.
  • Parker LA, Kwiatkowska M, Mechoulam R (2006). Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87: 6171.
  • Parker LA, Rana SA, Limebeer CL (2008). Conditioned disgust, but not conditioned taste avoidance: a measure of conditioned nausea in rats. Can J Exp Psychol 6: 198209.
  • Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, and Piomelli D (2009a). The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine- induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav 97: 121124.
  • Parker LA, Limebeer CL, Rana SA (2009b). Conditioned disgust, but not conditioned taste avoidance, may reflect conditioned nausea in rats. In: Reilly S, Schachtman TR (eds). Conditioned Taste Aversions: Behavioral and Neural Processes. Oxford University Press: NY.
  • Pavlov IP (1927). Conditioned Reflexes. (G.V. anrep, trans.). Oxford University Press: London, England.
  • Pertwee RG (2001). Cannabinoids and the gastrointestinal tract. Gut 48: 859867.
  • Pertwee RG (2004). The Pharmacology and Therapeutic Potential of Cannabidiol. DiMarzo V (ed.) Kluver Academic/Plenum Publishers: Cannabinoids.
  • Pertwee RG (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397411.
  • Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North American Study Group (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 295: 761775.
  • Rabin BM, Hunt WA (1983). Effects of anti-emetics on the acquisition and recall of radiation and lithium chloride induced conditioned taste aversions. Pharmacol Biochem Behav 18: 629636.
  • Racz I, Bilkei-Gorzo A, Markert A, Stamer F, Göthert M, Zimmer Z (2008). Anandamide effects on 5-HT3 receptors in vivo. Eur J Pharmacol 596: 98101.
  • Randall PA, Vemuri VK, Segovia KN, Torres EF, Hosmer S, Nunes EJ et al. (2010). The novel cannabinoid CB1 antagonists AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav 97: 179184.
  • Ray AP, Griggs L, Darmani NA (2009). Δ9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav Brain Res 196: 3036.
  • Reicher MA, Holman EW (1977). Location preference and flavor aversion reinforced by amphetamine in rats. Anim Learn Behav 5: 343346.
  • Reynolds DJM, Barber NA, Grahame-Smith DG, Leslie RA (1991). Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the antiemetic 5HT-3 receptor antagonist granisetron. Brain Res 565: 321336.
  • Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008). The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacol 196: 389395.
  • Rock EM, Limebeer CL, Fletcher PJ, Mechoulam R, Parker LA (2010). Cannabidiol (the non-psychoactive component of cannabis) may act as a 5-HT1A auto-receptor agonist to reduce toxin-induced nausea and vomiting. Poster presented at the Society for Neuroscience meeting, San Diego: CA.
  • Rudd JA, Naylor RJ (1996). An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol 118: 209214.
  • Rudd JA, Jordan CC, Naylor RJ (1996). The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 119: 931936.
  • Rudd JA, Ngan MP, Wai MK (1998). 5-HT3 receptors are not involved in conditioned taste aversions induced by 5-hydroxytryptamine, ipecacuanha or cisplatin. Eur J Pharmacol 352: 143149.
  • Russo EB, Burnett A, Hall B, Parker KK (2005). Agonist properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 10371043.
  • Schlicker E, Kathmann M (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: 571572.
  • Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ et al. (2007). Arvanil, anandamide and N-arachidonolyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 25: 27732782.
  • Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F et al. (2001). The cannabinoid agonist WIN 55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 94: 882886.
  • Sink KS, McLaughlin PJ, Brown C, Xu W, Fan P, Vemuri VK et al. (2007). The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33: 110.
  • Slatkin NE (2007). Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 5S: 19.
  • Sticht MA, Long JZ, Rock EM, Limebeer CL, Mechoulam R, Cravatt BJ et al. (2010). Effect of MAGL inhibitor, JZL184, on LiCl-induced emesis in the Suncus murinus and 2-AG on LiCl-induced conditioned gaping (a model of nausea) in rats. Poster presented at the Society for Neuroscience, San Diego: CA.
  • Stockhorst U, Klosterhalfen S, Klosterhalfen W, Winkelmann M, Steingrueber HJ (1993). Anticipatory nausea in cancer patients receiving chemotherapy: classical conditioning etiology and therapeutical implications. Integr Physiol Behav Sci 28: 177181.
  • Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G et al. (2010). Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120: 29532966.
  • Torii Y, Saito H, Matsuki N (1991). Selective blockade of cytotoxic drug-induced emesis by 5-HT3 receptor antagonists in Suncus Murinus. Jpn J Pharmacol 55: 107113.
  • Tramer MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323: 18.
  • Travers JB, Norgren R (1986). Electromyographic analysis of the ingestion and rejection of sapid stimuli in the rat. Behav Neurosci 100: 544555.
  • Tsukada H, Hirose T, Yokoyama A, Kurita Y (2001). Randomized comparison of ondansetron plus dexamethasone with desamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 37: 23982404.
  • Tuerke KJ, Limebeer CL, Lester J, Chambers J, Fletcher PJ, Parker LA (2010). Depletion of serotonin in the insular cortex by 5,7-Dihydroxytrptamine (5,7-DHT) lesions attenuates conditioned nauea in rats. Poster presented at the Society for Neuroscience meetings, San Diego.
  • Ueno S, Matsuki N, Saito H (1987). Suncus murinus: a new experimental model in emesis research. Life Sci 43: 513518.
  • Ungerleider JT, Andrysiak TA, Fairbanks LA, Tesler AS, Parker RG (1984). Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy. Radiology 150: 598599.
  • Van Belle S, Lichinitser M, Navari R, Garin AM, Decramer ML, Riviere A et al. (2002). Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK869. Cancer 94: 30323041.
  • Van der Stelt M, DiMarzo V (2004). Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 271: 18271834.
  • Van Sickle MD, Oland LD, HO W, Hillard CJ, Mackie K, Davison JS et al. (2001). Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121: 767774.
  • Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003). Δ9-Tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285: G566G576.
  • Van Sickle MD, Cuncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329332.
  • Wang Y, Ray AP, McClanahan BA, Darmani NA (2009). The antiemetic interaction of Δ9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol Biochem Behav 91: 367373.
  • Wegener G, Smith DF, Rosenberg R (1997). 5-HT1A receptors in lithium-induced conditioned taste aversion. Psychopharmacol 133: 5154.
  • Wise R, Yokel P, DeWit H (1976). Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats. Science 191: 12731274.
  • Wolff MC, Leander JD (1994). Antiemetic effects of 5-HT1A agonists in the pigeon. Pharmacol Biochem Behav 49: 385391.
  • Wolff MC, Leander JD (1995). Comparison of the antiemetic effects of a 5-HT1A agonist, LY228729, and 5-HT3 antagonists in the pigeon. Pharmacol Biochem Behav 52: 571575.
  • Wolff MC, Leander JD (1997). Effects of a 5-HT1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting. Eur J Pharmacol 340: 217220.
  • Yamakuni H, Sawai-Nakayama H, Imazumi K, Maeda Y, Matsuo M, Manda T et al. (2002). Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur J Pharmacol 442: 273278.
  • Yang KH, Galadari S, Isaev D, Petroianu G, Shippenberg TS, Oz M (2010). The nonpsychoactive cannabinoid cannabidiol inhibits 5-Hydroxytryptamine3A receptor-mediated currents in Xenopus laevis Oocytes. J Pharmacol Exp Therap 333: 547554.